Cancer

Items 41-50 of 68

per page
Set Descending Direction
  1. Parkin E3 Ligase TR-FRET Kit
    SBB-KF0036
    SBB-KF0036-KI011 Kit
    CHF 1'250.00
    Parkin E3 Ligase TR-FRET Kit
  2. PLpro (SARS Coronavirus) (rec.) (His)
    SBB-DE0024
    SBB-DE0024-C05050 µg
    CHF 278.00
  3. PLpro (SARS-CoV-2) (rec.) (His)
    SBB-DE0127
    SBB-DE0127-C05050 µg
    CHF 322.00
  4. SENP1 (catalytic domain) (human) (rec.) (His)
    SBB-DE0026
    SBB-DE0026-C05050 µg
    CHF 275.00
  5. Suc-Leu-Leu-Val-Tyr-AMC [Suc-LLVY-AMC]
    CAS  94367-21-2
    SBB-PS0010
    SBB-PS0010-M0022 mg
    CHF 101.00
    Suc-Leu-Leu-Val-Tyr-AMC [Suc-LLVY-AMC]
  6. SUMO1 (human) (rec.) (Rhodamine 110)
    SBB-PS0028
    SBB-PS0028-C05050 µg
    CHF 434.00
    Signal to Background: The signal to background ratio was determined by 100% hydrolysis of 200nM, 100nM, 50nM SUMO1-Rhodamine 110 to liberate the quenched conjugate. Assay Buffer: 50mM HEPES pH 7.5, 1mM TCEP, 0.1mg/ml BSA.
  7. SUMO2 (human) (rec.) (Rhodamine 110)
    SBB-PS0029
    SBB-PS0029-C05050 µg
    CHF 434.00
    Signal to Background: The signal to background ratio was determined by 100% hydrolysis of 200nM, 100nM, 50nM SUMO2-Rhodamine 110 to liberate the quenched conjugate. Assay Buffer: 50mM HEPES pH 7.5, 1mM TCEP, 0.1mg/ml BSA.
  8. TRF-Ubiquitin Mix (100X) (2000 reactions)
    SBB-TR0051-2K
    SBB-TR0051-2K-11 Vial
    CHF 5'255.00
    TRF-Ubiquitin Mix (100X) (2000 reactions)
  9. TRF-Ubiquitin Mix (100X) (400 reactions)
    SBB-TR0051-4H
    SBB-TR0051-4H-11 Vial
    CHF 1'233.00
    TRF-Ubiquitin Mix (100X) (400 reactions)
  10. UbcH1 [UBE2K, E2-25K] (human) (rec.) (His)
    SBB-CE0022
    SBB-CE0022-C100100 µg
    CHF 345.00
    Thioester Activity Assay: UBE2K forms a thioester with Ub in an ATP-dependent manner and the bond can be reduced with addition of excess DTT. The thioester assay also shows di-ubiquitin formation with addition of ATP. This confirms the activity of

Items 41-50 of 68

per page
Set Descending Direction
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.